Zimmer Biomet Stock Price, News & Analysis

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) has announced the appointment of David DeMartino as Senior Vice President, Investor Relations, effective September 9, 2024. Reporting to CEO Ivan Tornos, DeMartino will lead the company's investor relations strategy and manage relationships with the investment community. With over 25 years of experience in healthcare, including asset management and equity research, DeMartino brings valuable industry knowledge to the role.

Prior to joining Zimmer Biomet, DeMartino served as Chief Strategy Officer at Nyxoah and held positions at DNB Asset Management, Velan Capital, Citadel, and Pura Vida Investments. His background also includes sell-side equity research at Deutsche Bank and Credit Suisse, as well as investment banking experience.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, has announced a quarterly cash dividend for the third quarter of 2024. The company's Board of Directors has approved a dividend of $0.24 per share, which will be payable on or about October 31, 2024 to stockholders of record as of the close of business on September 30, 2024. This announcement demonstrates Zimmer Biomet's commitment to providing regular returns to its shareholders and reflects the company's financial stability.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, has announced its participation in two major healthcare conferences in September 2024. The company's management team will present at the Wells Fargo 2024 Healthcare Conference on September 5 at 8:00 a.m. ET, followed by a presentation at the Morgan Stanley Annual Global Healthcare Conference on September 6 at 9:15 a.m. ET.

Investors and interested parties can access live webcasts of both presentations through Zimmer Biomet's Investor Relations website. These webcasts will also be archived for later viewing. This participation in high-profile healthcare conferences demonstrates Zimmer Biomet's commitment to engaging with the investment community and sharing insights about their business and industry trends.

Zimmer Biomet (NYSE: ZBH) reported strong Q2 2024 financial results, with net sales of $1.942 billion, up 3.9% year-over-year and 5.6% on a constant currency basis. Diluted earnings per share were $1.18, while adjusted diluted EPS reached $2.01. The company's performance was driven by customer demand for its diversified products and strong international business. Zimmer Biomet updated its 2024 reported revenue guidance due to currency expectations but reaffirmed constant currency revenue growth and adjusted EPS guidance. Notable highlights include the acquisition of OrthoGrid Systems, a partnership with THINK Surgical for robotic systems, and a co-marketing agreement with RevelAi Health for AI-powered technology.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) has announced a definitive agreement to acquire OrthoGrid Systems, Inc., a privately-held medical technology company specializing in AI-driven surgical guidance systems for total hip replacement. The acquisition includes OrthoGrid's Hip AI® platform, two additional FDA-cleared orthopedic applications, and over 40 patents.

OrthoGrid's fluoroscopy-based surgical guidance system offers real-time X-ray imaging, improving surgical accuracy and efficiency without the need for preoperative CT scans. The Hip AI system provides real-time image analysis, automated measurements, and guidance on optimal cup placement, allowing surgeons to tailor the system to their specific techniques.

The acquisition is expected to close by the end of Q4 2024, subject to customary conditions.

Zimmer Biomet has announced it will webcast its Q2 2024 earnings conference call on August 7, 2024, at 8:30 a.m. ET. The quarterly financial results will be released earlier that day at 6:30 a.m. ET.

The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website, with a replay available post-call. U.S. and Canadian participants can join the call by dialing (888) 204-4368 and using conference ID 5103691, while international participants should dial +1 (323) 994-2093 with the same ID.

Zimmer Biomet has announced the appointment of Devdatt Kurdikar to its Board of Directors, effective immediately. Kurdikar is currently the President, CEO, and a board member of Embecta, a leading diabetes management company. His extensive experience in the medical technology sector includes leadership roles at BD, Cardiac Science, Boston Scientific, and Baxter International. Zimmer Biomet's Chairman, Chris Begley, emphasized the value Kurdikar's expertise will bring as the company advances its strategic priorities. Kurdikar holds advanced degrees in Chemical Engineering and an MBA, and has a strong background in medtech innovation and leadership.

RevelAi Health and Zimmer Biomet have announced a multi-year co-marketing agreement aimed at advancing value-based orthopedic care and health equity through AI-powered technology. Zimmer Biomet will commercialize RevelAi Health's patient care-management platform and additional future products. The partnership focuses on leveraging generative AI to improve clinical workflows, address socio-demographic disparities, and enhance patient engagement. RevelAi Health's platform meets essential CMS requirements and includes a unique patient care management system utilizing text messaging and voice agents. This collaboration aims to ensure equitable, value-based outcomes for all patients, particularly underserved communities.

Zimmer Biomet, a global medical technology leader, announced a distribution agreement with THINK Surgical for the TMINI Miniature Robotic System, a handheld device for total knee arthroplasty. The TMINI system complements Zimmer Biomet's ROSA Robotics portfolio, offering accurate implant placement based on a CT-based surgical plan. This partnership enables Zimmer Biomet to be the first medtech company to offer two robotic systems for knee replacements, catering to surgeon demand for ergonomic and wireless solutions. The TMINI system is aimed at ambulatory surgery centers and outpatient settings, with a U.S. market introduction planned for the second half of 2024.